Elsevier

Thrombosis Research

Volume 17, Issues 3–4, 1–15 February 1980, Pages 317-327
Thrombosis Research

Paper
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

https://doi.org/10.1016/0049-3848(80)90066-3Get rights and content

Abstract

We studied the time- and dose-dependence of the inhibitory effect of oral aspirin on platelet production of thromboxane (TX) B2 in response to endogenously formed thrombin, by allowing the whole blood to clot at 37°C for 30 min and measuring TXB2 concentrations by radioimmunoassay in the separated serum. The concentrations of generated TXB2 averaged 222.4 ± 81.3 (SD) ng/ml of serum in 45 healthy subjects, and were highly reproducible in the same subject upon repeated sampling. A single 100-mg aspirin dose reduced serum TXB2 by 98% during the 1st hour. Single doses of 100–400 mg aspirin resulted in 94–98% inhibition after 24 and 48 h, and 90–92% after 72h. Thereafter, serum TXB2 returned to control levels with a time course consistent with platelet turnover. More than 90% inhibition could be maintained, over one month, by giving a 200-mg aspirin dose every 72h. Thus, aspirin can achieve a ceiling effect on TXB2 production in healthy subjects at a considerably lower dosage than currently employed regimens for antithrombotic therapy.

References (31)

  • G.J. Roth et al.

    Modification by aspirin of the amino terminal serine of Prostaglandin synthetase

    Clin. Res.

    (1978)
  • J.B. Smith et al.

    Aspirin selectively inhibits prostaglandin production in human platelets

    Nature (New Biol.)

    (1971)
  • M. Hamberg et al.

    Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation

  • M. Hamberg et al.

    Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

  • P.W. Majerus

    Why aspirin?

    Circulation

    (1976)
  • Cited by (559)

    • Precision antiplatelet therapy

      2023, Research and Practice in Thrombosis and Haemostasis
    • Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy

      2023, Obstetrics and Gynecology Clinics of North America
    • Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A<inf>2</inf> is unrestrained

      2021, Pharmacological Research
      Citation Excerpt :

      First, we assessed whether the administration of this dose of Aspirin affected platelet COX-1 activity. As shown in Fig. 4E, in IPKO and WT mice fed with a high-salt diet, Aspirin profoundly inhibited the production of serum TXB2 (i.e., a capacity index of platelet COX-1 activity) [24] (93.8 ± 3 and 93.2 ± 3.5%, respectively). Aspirin also caused a marked reduction of the urinary levels of TXM (Fig. 4A) both in WT and IPKO mice fed with a high-salt diet.

    View all citing articles on Scopus
    View full text